The LVAD trial is a bit more complex for MSB since it was not their trial and they are a bit at the mercy of the the NIH scientist and doctors (who are probably all sitting at home at the moment). The data we have got from that trial does look positive for the CHF trial.
The GI bleed effect looks real too, but if the insurance companies are going to be willing to pay to stop it is unknown. We really need the data on the reason for other admissions to know. I suspect the FDA will want more trials, but who knows given the size of the population. I look at it as a bonus rather than critical to MSB success.
Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-35
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.045(4.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 94.5¢ | $2.669M | 2.769M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2053 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 13191 | 2 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |